Stay updated with breaking news from Nasdaq Imrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Mizuho started coverage on shares of Immuneering (NASDAQ:IMRX – Get Rating) in a research report released on Wednesday, The Fly reports. The firm issued a neutral rating and a $10.00 price objective on the stock. Several other analysts have also recently weighed in on IMRX. Chardan Capital reiterated a buy rating and issued a $18.00 […]
Stock analysts at Mizuho started coverage on shares of Immuneering (NASDAQ:IMRX – Get Rating) in a research note issued to investors on Wednesday, The Fly reports. The firm set a “neutral” rating on the stock. IMRX has been the subject of a number of other research reports. Chardan Capital reiterated a “buy” rating and set […]
Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day. Thus, choosing the right small-cap stocks can offer
CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational...
Immuneering (NASDAQ:IMRX – Get Rating) and Pacira BioSciences (NASDAQ:PCRX – Get Rating) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk. Insider and Institutional Ownership 47.4% of Immuneering shares are held by […]